1. Introduction {#s0005}
===============

*Mycoplasma hominis* (*M. hominis*) is a mollicute that colonizes the urogenital tract and occasionally causes invasive disease. Extra-genital infections with this organism occur primarily in immunosuppressed persons. *M. hominis* has been linked to pregnancy-related complications and causes meningitis and pneumonia in neonates ([@bb0030], [@bb0125], [@bb0165]). *M. hominis* is not visualizable by gram stain due to its lack of a cell wall, and although it may grow on standard aerobic or anaerobic bacterial culture plates, this method is insensitive and requires highly experienced laboratory personnel to recognize colonies of *M. hominis*. *M. hominis-*specific culture may be performed, but are not widely available, and even if they are available, is not rapid. The route of acquisition of *M. hominis* in patients who undergo cardiothoracic transplantation has not been defined. In two prior reports in *Chest* the authors speculated 1) the organism entered the bloodstream (though blood cultures were negative) of a lung transplant recipient who developed pleural and pulmonary infection with *M. hominis*. These authors speculated manipulation of the urinary tract with a Foley catheter elicited invasion of lung tissue damaged by transplantation ([@bb0080]) and 2) an 18 year old women developed diffuse alveolar hemorrhage following bone marrow transplant due to unproven airway or urinary tract colonization ([@bb0075]). Herein, we describe seven new cases of *M. hominis* infection in cardiothoracic transplant recipients and review the literature on the topic. We highlight the unique clinical presentation of *M. hominis* in this patient population and present evidence suggesting that this infection may be donor-transmitted. *M. hominis* should be considered in the etiological diagnosis of surgical site infections, mediastinitis and pleuritis after lung or heart-lung transplantation; use of *M. hominis*-specific PCR may expedite diagnosis.

2. Methods {#s0010}
==========

The study was reviewed and approved by the Mayo Clinic Institutional Review Board (14-007214). Individual patient consent was not needed.

2.1. Case Detection {#s0015}
-------------------

Using our heart and lung transplant database and chart review (between 1998 and July 2015) we found seven (among 182 lung transplants and heart-lung performed and 453 heart transplants) previously unreported cases of culture positive *M. hominis* infection in cardiothoracic transplant recipients ([Table 1](#t0005){ref-type="table"}). In each case routine cultures grew *M. hominis* and no other bacterial pathogens were identified. PCR for *M. hominis* (beginning January 2014), *Ureaplasma urealyticum*, and *Ureaplasma parvum* (beginning January 2015) were requested when suspected infection sites were gram stain negative, and early bacterial cultures were negative with the presence of white blood cells. *M. hominis*, *Ureaplasma urealyticum*, and *Ureaplasma parvum* PCR were specifically performed prospectively on all donor airway specimens beginning in 2015. Importantly, in each case reported herein *M. hominis* was the only infectious agent identified. None of these *M. hominis* cases developed hyperammonemia and none of these cases tested positive for *Ureaplasma* sp. However, we have recently identified a single case of donor bronchus which tested as *M. hominis* PCR negative and *Ureaplasma urealyticum* PCR positive as well as a single case of donor bronchus which tested as *M. hominis* PCR positive and *Ureaplasma urealyticum* PCR negative. Both cases were treated prophylactically without evidence of disease. All *M. hominis* cases and donor surveillance cases were reported to the host organ procurement organization as required by the Organ Procurement Transplant Network. Prior to 2009 all patient received cytolytic induction, after 2009 only heart recipients received cytolytic induction. All patients received intraoperative methylprednisolone. Post-transplant immunosuppression is listed in [Table 1](#t0005){ref-type="table"}.Table 1Summary of 7 Mayo Clinic cases of *Mycoplasma hominis* infection in thoracic transplant recipients.Table 1Case tran-plant\
(year)Age (years) SexTransplant indicationTransplant type\
Immune suppressionSigns or symptoms (days after transplant)Clinical presentationMethod used to diagnose *M. hominis* infectionSurgical managementAntimicrobial therapyOutcomeA (2000)44MSecondary pulmonary hypertensionHL\
ATG/CSA/AZA/PredSternal site infection with sternal dehiscence (15)Sternal wound infectionCulture-positive surgical debridement specimensDebridement and sternectomyDoxycycline and ciprofloxacin × 10 yearsRecoveredB (2009)69MIdiopathic pulmonary fibrosisSL\
ATG/Tacro/AZA/PredDyspnea, unilateral pleural effusion (14)PleuritisCulture positive pleural fluidCatheter drainage of pleural fluidLevofloxacin for 3 weeksRecoveredC (2011)41FPulmonary hypertensionHL\
ATG/Tacro/Mycop/PredDyspnea, cough with progression to circulatory shock in 48 h (19)Mediastinitis with aortic anastomotic leakCulture positive pericardial fluid, periaortic tissue and BAL fluidMediastinal debridement (3)Clindamycin for 4 weeks then doxycycline (lifelong)*Recovered*D (2014)64MIdiopathic pulmonary fibrosisSL\
Tacro/AZA/PredDyspnea, loculated pleural effusion (16)PleuritisPCR- and culture-positive pleural fluidThoracotomy and debridementLevofloxacin and doxycycline for 6 weeks, followed by doxycycline for 6 monthsSlow recovery with multiple subsequent infectious complicationsE (2015)64MChronic obstructive lung diseaseSL\
\
Tacro/AZA/PredFever, leukocytosis and a loculated hydropneumothorax (7)PleuritisPCR- and culture-positive pleural fluid; culture positive debridement specimens (multiple)Thoracotomy and debridement, wound VACDoxycycline (lifelong)RecoveredF (2015)70MIdiopathic pulmonary fibrosisSL (same donor as D)\
Tacro/AZA/PredDyspnea, and loculated pleural effusion (21)PleuritisPCR- and culture-positive pleural fluid; culture-positive central venous catheter tipPleural fluid aspirationDoxycycline (lifelong)RecoveredG (2015)63MIdiopathic pulmonary fibrosisBL\
Tacro/Myco/PredSubcutaneous emphysema (63)Right bronchial anastomotic leakPCR positive from both pretransplant donor bronchi and recipient pleural fluid; culture positive from both pretransplant donor brochi and later bronchial anastomotic escharDelayed bronchial anastomotic healingLevofloxacin and doxycycline (lifelong)Recovered[^1]

2.2. Literature Review {#s0020}
----------------------

PubMed was queried beginning in 1950 for *M. hominis* infection and cardiothoracic transplantation.

2.3. Surveillance Detection of *M. hominis* DNA in BAL Fluid from Non-cardiothoracic Transplant Immunocompromised Patients {#s0025}
--------------------------------------------------------------------------------------------------------------------------

BAL samples submitted for detecting organisms commonly found in immunocompromised hosts undergoing clinically indicated bronchoscopy were tested for *M. hominis* DNA. We used a previously-described real-time PCR assay targeting *M. hominis tuf* ([@bb0035]). DNA was extracted on the MagNA Pure LC instrument using the MagNA Pure total nucleic acid isolation kit (Roche Applied Science, Indianapolis, IN).

3. Results {#s0030}
==========

3.1. Patient Evaluation and Donor Characteristics {#s0035}
-------------------------------------------------

All patients received standard immunosuppression. All patients had pre-transplant sputum cultures which were negative for *M. hominis*. Routine perioperative bacterial prophylaxis included Vancomycin for 48 h and Cefepime for 48--72 h. Trimethoprim/sulfamethoxasole was typically begun on post-operative day 2 or 3. Any additional bacterial prophylaxis was based upon donor and recipient airway cultures. In all cases clinical signs, including prolonged pleural effusion, prompted routine bacterial and fungal cultures of suspected sites of infection. *M. hominis* was consider etiologic if routine cultures were negative and *M. hominis* was identified by culture or PCR in presumed sterile sites. Donor characteristics are summarized in [Table 2](#t0010){ref-type="table"}. Although our observations are limited to seven distinct donors among eight recipient cases (including a previously reported case [@bb0175]), several characteristics are noted. The average donor age was 19.7 years (16--23). Six of seven donors had a history of, or tested positive for, drugs of abuse, including methamphetamine and marijuana. In addition, 5 of 7 donors were known tobacco users.Table 2Donor characteristics associated with the cases described in table and our case described in Reference ([@bb0175]).Table 2CaseDonor age (years) SexDonor raceDonor serologiesDrug screenOther drug historyTobaccoDonor mechanism of deathA22 FCaucasianCMV +/EBV +Methampetamine, tricyclic antidepressant, acetaminophen, aspirinAlcoholNoDrug overdoseB23 MHispanicCMV +/EBV +Marajuana, ETOHAlcoholYesCHIC19 MCaucasianCMV +/EBV +NegativeMarajuanaNot knownCHID/E16 MAfrican AmericanCMV +/EBV +NegativeMarajuanaYesGSW to headF23 MCaucasianCMV −/EBV +NegativeAlcoholYes, chewingCHI/MVAG19 FCaucasianCMV +/EBV +MethampetamineAlcoholYesCHI/MVARef ([@bb0175])16 MAfrican AmericanCMV +/EBV +MarajuanaAlcoholYesCHI/MVA[^2]

3.2. Literature Review {#s0040}
----------------------

Our review of the literature since 1950 identified 15 cases of *M. hominis* infection in lung, heart or heart-lung transplant recipients ([Table 3](#t0015){ref-type="table"}), one of which was reported from our institution ([@bb0175]). Including our seven new cases, the mean age of the 22 recipients was 47.9 years with 72.7% being male. Pulmonary hypertension, chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis were the most frequent indications for transplantation. Patients developed symptoms a mean of 17.1 days (range 4--63 days) following transplantation. Fever was reported in 8/22 (36%). Pleural/pericardial effusion, chest wall/sternal wound infection, or *M. hominis* bacteremia was evident in 13 (59%) and 12 (55%), and 2 (9%), respectively. All 13 patients with pleural effusions had positive pleural fluid cultures for *M. hominis*. Twelve (55%) patients had *M. hominis* cultured from more than one site; *M. hominis* was isolated from BAL fluid in seven cases.Table 3Literature review of thoracic transplant recipient infection with *Mycoplasma hominis*.Table 3Case\
(Ref)Age (years) SexTransplant indicationTransplant typeSigns or symptoms (days after transplant)Cultures positive for *M. hominis*Surgical managementAntimicrobial therapyOutcome1 ([@bb0070])52 MBronchiectasisBLBilateral pleural effusions, thoracotomy dehiscence, bronchial anastomostic dehiscence (14)Wound swab and debrided tissueBronchial stent placementClindamycin and ciprofloxacin followed by oral doxycycline for 6 weeksRecovered2 ([@bb0070])*55 MIschemic cardiomyopathyH*Sternal dehiscence, fever (8)Sternal wound swab, pleural fluidSurgical debridement, drainage*Ciprofloxacin and doxcycline for 14 days*Recovered3 ([@bb0070])21 MDilated cardiomyopathyHSternal wound infection (14)Sternal wound, pericardial and pleural fluidSurgical debridement, drains*Ciprofloxacin and doxcycline*Recovered4 ([@bb0070])17 MBecker cardiomyopathyHSternal wound, pleural effusion (21)Sternal wound, pericardial and pleural fluidSurgical irrigation*Ciprofloxacin and doxcycline for 3 weeks*Recovered5 ([@bb0080])34 MAPL and pulmonary hypertensionBLPulmonary infiltrates, pleural effusions (5)Pleural fluid, bronchial brush specimen, lung biopsySurgical debridementDoxycycline for 4 weeksRecovered, replased *M. hominis* sternal wound infection on day 1086 ([@bb0090])64 MEmphysemaBLTachycardia, tachypnea (36)Pericardial fluidPericardiocentesisDoxycycline for 6 weekRecovered7 ([@bb0145])30 FPulmonary hypertensionHLCough (3), unstable sternum, fever (24)Sternum, BALSurgical debridement + muscle flapClindamycin and doxycycline and gentamicin; duration unknownDied, day 69 post-transplant8 ([@bb0145])43 FPulmonary hypertensionHLDyspnea, pulmonary infiltrates (13), erythema sternal tenderness (17)Sternal wound,\
BALSuperficial I&D with wound packingDoxycycline and clindamycin and gentamicinDied, day 37 post-transplant9 ([@bb0025])48 MEisenmenger syndromeHLUnstable sternum, fever (30)Sternal woundSurgical debridement + muscle flap over sternumDoxycycline for 6 weeksRelapse of *M. hominis* empyema seven months later. Placed on doxycycline suppression10 ([@bb0095])41 MCystic fibrosisBLSternal wound drainage (22)Sternal wound cultureSurgical debridement and omental muscle flapErythromycin for 14 weeksRecovered11 ([@bb0055])65 MAlpha-1 antitrypsin deficiencyBLPulmonary infiltrates, pleural effusion, fever (7)Pleural fluid, BALNot availableCiprofloxacin for 4 weeksRecovered12 ([@bb0055])50 MEmphysemaSLPleural effusion, dyspnea (5)Pleural fluidNoneCiprofloxacin for 4 weeksRecovered13 ([@bb0085])31 FNot availableHLSternal wound drainage, fever (6)BAL, sternal wound cultureDebridement + muscle flapsClindamycin and doxycycline for 3 weeksDied[a](#tf0005){ref-type="table-fn"}14 ([@bb0085])43 FNot availableHLSternal wound drainage, fever (13)BAL, sternal woundUnknownClindamycin and doxycycline for 3 weeksDied[b](#tf0010){ref-type="table-fn"}15 ([@bb0175])64 FIdiopathic pulmonary fibosisBLConfusion, fever, pulmonary infiltrates, coma, hyperammon-emia (4)Catheter tip (multiple post-mortem tissues PCR positive for *M. hominis*)NoneCiprofloxacinDied[^3][^4][^5]

3.3. Detection of *M. hominis* DNA in BAL Fluid from Immunocompromised Patients {#s0045}
-------------------------------------------------------------------------------

In 178 BAL samples obtained from random immunocompromised non-cardiothoracic transplant patients submitted for detecting organisms commonly found in immunocompromised hosts *M. hominis* DNA was not detected in any specimen.

3.4. Assessment for Donor-derived Infection {#s0050}
-------------------------------------------

In our Case B of culture proven *M. hominis* single lung transplant associated pleuritis, the donor\'s other lung was transplanted into a 67 year old female (not included in this report) at our institution who developed superficial wound cellulitis, chest pain and a right-sided hydropneumothorax in the second week post-surgery. A pleural pigtail catheter was placed and routine bacterial cultures on standard media were negative. *M. hominis* PCR testing was not performed. However, imaging showed persistent pleural thickening with fluorodeoxyglucose uptake in the right thoracic cage. She received levofloxacin for diverticulitis and improved clinically. Together, this data suggest the possibility of undiagnosed *M. hominis* infection.

In case G, the donor bronchus culture swab was PCR positive for *M. hominis*. Levofloxacin was given for 2 weeks and doxycycline (lifelong) in addition to standard prophylaxis with Vancomycin and Cefepime. Recently, (data not included) we have prophylactically treated one patient whose donor bronchus culture swab was PCR positive for *M. hominis* and one patient who\'s donor bronchus culture swab was PCR positive for *Ureaplasma urealyticum*. Each patient was treated with doxycycline for 28 days.

Cases E and F ([Table 1](#t0005){ref-type="table"}, [Fig. 1](#f0005){ref-type="fig"}) had received single lung transplants from the same donor and each case had transplant site specific infection. Multilocus sequence typing (MLST) was performed on isolates recovered from these two cases and two additional reference isolates (a clinical isolate and the type strain ATCC 23114), using methods described by Sogaard et al. ([@bb0140]). Briefly, PCR was performed targeting housekeeping genes, *tuf*, *ftsY*, *hitB-hitL*, *uvrA* and *gap*, followed by bidirectional Sanger sequencing. Sequencing data were analyzed (trimming and contig assembly) with the CLC Genomics Workbench (CGW) version 8.0.3 (CLC bio, Cambridge, MA) sequence analysis module. For each target, sequences were aligned and identities calculated using the CGW alignment and tree module. Alignments of the housekeeping genes were joined and a phylogenetic tree constructed using the CGW alignment and tree module. Maximum-likelihood and neighbor joining trees with Jukes-Cantor correction and bootstrap analysis (1000 replicates) were constructed with the CGW software. Isolates recovered from cases D and E were indistinguishable by MLST, with no base pair differences across the five sequenced housekeeping genes (3094 bases). These results suggest common source infection, such as donor-derived infection. No other patients on their hospital unit, other hospital units, or under their surgeons care were infected by *M. hominis*.Fig. 1Phylogenetic tree based on multilocus sequence typing showing the *M. hominis* isolates from case D (MBRL 1161) and case E (MBRL 1162) to be indistinguishable. The spine isolate represents an isolated from a contemporaneous clinical case of *M. hominis* spinal osteomyelitis; ATCC 23114 is the reference strain.Fig. 1

4. Discussion {#s0055}
=============

*M. hominis* infection in cardiothoracic transplant recipients has been uncommonly reported. The true infection rate may be underestimated in view of difficulties in detecting the organism in clinical specimens and in the use of antibiotic prophylaxis and empiric antimicrobial regimens, such as fluoroquinolones, that do target *M. hominis*. Cardiothoracic transplant patients sustain all of the risks for infection generally encountered in the routine practice of cardiovascular surgery, including *Staphylococcus* species, *Pseudomonas*, and *Serratia*, but fungi especially *Aspergillus* species and *Candida* contribute importantly ([@bb0150]). Donor transmission of infection remains important. Surveillance cultures of donor and recipient, and antimicrobial prophylaxis remain the cornerstone of infection prevention. In the report herein, we note infection with *M. hominis* in the absence of other known infection. The manifestations were often delayed after transplantation by several weeks, and included pleuritis with cellulitis, trapped lung, delayed airway anastomotic healing, and aortic and sternal dehiscence. Treatment included surgical intervention and long-term antibiotics.

*M. hominis* is not stainable by Gram stain and recognition of its pinpoint-sized colonies requires experienced laboratory personnel. BacT/ALERT and BACTEC media (used for blood cultures) contain sodium polyanethol sulfonate, which may inhibit *Mycoplasma* growth ([@bb0160]), and growth may not exceed the threshold value for positivity ([@bb0160]). Selective *M. hominis* culture media may be useful but remain laborious and expensive.

Since the mid-1990s DNA probe methods using PCR to identify the nucleotide sequences of *M. hominis* have been developed which seek to avoid diagnostic time delays while offering the sensitivity and specificity of conventional culture methods ([@bb0185]). PCR assays have been designed to target the glyceraldehyde-3-phosphate dehydrogenase gene (*gap*) ([@bb0170]), *yidC* ([@bb0190]), the *M. hominis* 16S ribosomal RNA gene ([@bb0130]), and, as used herein, *tuf* ([@bb0035]). We previously reported (in genitourinary specimens) a clinical sensitivity and specificity of 90.7% (95% CI: 77.4%, 97.3%) and 99.2% (95% CI: 97.0%, 99.9%), respectively ([@bb0035]). For the detection of *M. hominis* PCR tests are faster than culture tests using media supplemented with arginine, allowing the time to diagnosis to be reduced from two to five days to \< 24 h ([@bb0005]). To date the Federal Drug Administration Center for Devices and Radiologic Health has not approved a nucleic acid based test for the detection of *M. hominis*. Thus, in the U.S. transplant physician will need to consider reference laboratories to perform PCR testing as well as dedicated *M. hominis* cultures and empiric treatment for suspected cases of *M. hominis* infection.

The mode of acquisition of *M. hominis* in cardiothoracic transplant recipients has been uncertain. Colonization rates of donors and recipients have hitherto been uncharacterized ([@bb0160]). Lacking the genes coding for a cell wall appears to limit *M. hominis* to a parasitic and saprophytic existence. There are no known natural reservoirs for *M. hominis* though it has been recovered from random public toilet rims ([@bb0115]). *M. hominis* is part of the normal urogenital flora, suggesting a potential endogenous source. Thus, others have speculated without data that *M. hominis* enters the bloodstream from manipulation of the urethra by Foley catheter placement in colonized recipients ([@bb0080]). This rationale is supported by the finding of *M. hominis* sternal wound infection in non-immunocompromised patients undergoing coronary artery bypass grafting without transplantation ([@bb0145]). A case cluster involving four cases alluded to a common environmental source ([@bb0065], [@bb0070]), with a suspicion of nosocomial transmission in the four reported cases of *M. hominis* infection occurring over three weeks in the same hospital ([@bb0070]).

Primary immunodeficiencies are associated with sepsis and septic arthritis due to *M. hominis*. Most reports include patients with common variable immunodeficiency or X-linked agammaglobulinemia ([@bb0020]). Though postpartum septicemia caused by *M. hominis* may be due to genitourinary bacterial translocation ([@bb0155]), immunodeficiency cases commonly are not associated with urinary tract manipulation. This suggests that dissemination of *M. hominis* may be from acquired from sites outside the genitourinary tract. Though the mechanism(s) required for immunocompetence against *M. hominis* is not clear, we note that in all of our cases pre-transplant immunoglobulin IgA, IgM, IgG and IgG subclasses were determined and values were normal (data not shown) in all cases.

The colonization rate of heart and lung transplant donors with *M. hominis* is not known and may be different from the general population. *M. hominis* may induce exudative pharyngitis ([@bb0105]) and older reports using culture suggest reported it to be recoverable from the respiratory secretions of 1--3% of healthy persons ([@bb0060]) and of ≤ 8% of persons with chronic respiratory disease ([@bb0100]). Thus, there is the possibility of transmission related to donor airway colonization, or organ contamination during organ procurement. Donor oral sexual practice may be a risk factor for *M. hominis* airway colonization as oral sex has been noted as an important route of transmission for *M. hominis* ([@bb0040], [@bb0120]). Our review of the literature ([Table 3](#t0015){ref-type="table"}, cases 11 and 12) describes two recipients who had received lungs from the same donor, supporting the possibility of a donor-derived infection ([@bb0055]). Two of their cases (heart and bilateral lung recipients) shared the same donor, although cultures of donor bronchus did not grow *M. hominis*; it is unknown whether *M. hominis*-specific cultures were performed.

Our observations in cases B, E, F, and G suggest that in cardiothoracic transplant recipients, donor-derived acquisition of *M. hominis* is possible. The likelihood that the disease is of donor origin fulfills the term probable donor transmission established by Project NOTIFY ([@bb0050]) as (1) we cannot exclude pre-transplant disease in the recipient; but (2) the disease was documented in more than one recipient (cases E and F) and (3) we provide epidemiologic evidence reporting that in cases D and E there was strain as the isolates were indistinguishable via MLST. Due to a lack of residual specimen, it was not possible to isolate the organism from the donor respiratory tract via culture or detect it by PCR. However, in case G, a donor bronchus swab (the first swab we tested prospectively) tested positive PCR for *M. hominis*. Our surveillance data showing the absence of *M. hominis* DNA by PCR in the BAL samples of unselected immunocompromised hosts suggests that a positive test should be considered significant in the appropriate clinical context. Further studies are needed to evaluate the correlation between clinical infection in cardiothoracic transplant recipients and *M. hominis* positivity in the donor respiratory tract.

We have previously reported detection of *M. hominis* infection in a case of post-lung transplant hyperammonemia ([@bb0175]); the patient had a positive central venous blood culture for *M. hominis* and PCR and immunofluorescence detection of *M. hominis* in multiple post-mortem tissues. Follow-up testing showed the patient to have been co-infected with *Ureaplasma parvum* ([@bb0015]). In follow-up studies, *Ureaplasma* species, both *U. parvum* and *Ureaplasma urealyticum* (without *M. hominis*) were shown to be associated with hyperammonemia in five other lung transplant recipients ([@bb0015]). Therefore, whether or not *M. hominis* plays a role in hyperammonemia in lung transplant patients is unclear. In our cases D, E, F, and G, blood ammonia determined and was not elevated, suggesting that non-systemic *M. hominis* infection is insufficient to cause hyperammonemia in lung transplant recipients.

As *M. hominis* does not produce peptidoglycan, cell wall active antibiotics like β-lactams and vancomycin, commonly used post-transplant, are ineffective. Moreover, *M. hominis* does not require folate and is resistant to folate antagonists (such as trimethoprim/sulfamethoxazole); it is also resistant to aminoglycosides ([@bb0135]). *M. hominis* is naturally resistant to 14- and 15-membered macrolides, including erythromycin and azithromycin, but is usually susceptible to clindamycin ([@bb0045]). One study tested 110 clinical isolates of *M. hominis* and found levofloxacin to be inhibitory in all instances, with an MIC~90~ of 0.19 μg/ml ([@bb0125]). Treatment recommendations for *M. hominis* infection therefore include tetracyclines (doxycycline is preferred), fluoroquinolones and/or clindamycin. Importantly, tetracyclines, fluroquionolones and clindamycin are not typically included in standard post-transplant prophylactic regimens, nor are they typically included in empiric therapy regimens for surgical site infections. The *tet*(M) determinant confers tetracycline (and doxycycline) resistance; the prevalence of tetracycline resistance in *M. hominis* varies by geographic location and may be as high as 30% ([@bb0110], [@bb0125], [@bb0180]). Although susceptibility testing should be used when available, in the absence of definitive evidence, we suggest that combination therapy with a fluoroquinolone and doxycycline may be a preferred regimen for established *M. hominis* infection in cardiothoracic transplant recipients, given the possibility of tetracycline resistance and the potential for selection of fluoroquinolone resistance with fluoroquinolone monotherapy ([@bb0010]). The optimal duration of therapy for *M. hominis* infection in cardiothoracic transplant recipients is not known.

In summary, *M. hominis* is a cause of cardiothoracic transplant infection, presenting with pleuritis, surgical site infection, and/or mediastinitis. We provide evidence that this infection is probably donor-derived. Rapid PCR is an expedient method of detection, used to diagnose four of seven of the cases reported, but does not replace culturing the organism to determine the susceptibility profile. Our current approach is to perform routine PCR for *M. hominis*, *Ureaplasma urealyticum* and *U. parvum* and to perform bacterial culture all donor airways. We perform the same PCR tests on any suspected surgical site infection which is gram stain negative. In addition, we reflexively culture any PCR-positive specimens (e.g., pleural fluid) from cardiothoracic transplant recipients for the purpose of susceptibility testing. Currently, most antibiotic prophylaxis regimens, and regimens for empirical therapy of post-transplant infectious complications do not cover *M. hominis*. Prospective studies are needed to assess the correlation between donor airway positivity for *M. hominis* and clinical infection in transplant recipients.
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[^1]: M, male; F, female; HL, heart-lung transplant; BL, bilateral lung transplant; SL, single lung transplant; BAL, bronchoalveolar lavage; ATG, antithymocyte globulin; Tacro, tracrolimus; AZA, azathioprine; Pred, prednisone; Myco, mycophenolate mofetil.

[^2]: M, male; F, female; CMV, cytomegalovirus; EBV, Epstein-Barr virus; GSW, gun shot wound; CHI, closed head injury; MVA, motor vehicle accident.

[^3]: M, male; F, female; HL, heart-lung transplant; BL, bilateral lung transplant; SL, single lung transplant; BAL, bronchoalveolar lavage; H, heart; APL, antiphospholipid antibody syndrome.

[^4]: After complications with rejection & respiratory failure. Cultures for *M. hominis* were negative at that time.

[^5]: Developed an unstable sternum and CMV pneumonitis.
